. He can be reached at nsaraceno@mjhlifesciences.com.

Podcasts

While studies reveal the complex, varying, and long-lasting burden of Long COVID symptoms, biopharma giants Novartis and Moderna commit significant capital to new facilities, reinforcing US drug supply resilience in today’s Pharma Pulse.

Pharma Pulse: Long COVID's Enduring Challenge Amid Major US Manufacturing Surge

In today’s Pharma Pulse, we dissect the resource drain of new pilot programs, the growing concerns over global supply chain dependency, and the simple tech intervention improving glycemic control.

Pharma Pulse: Regulatory Crucible, China Supply Risk, and Texting Triumphs in Diabetes Care

In today’s Pharma Pulse, learn how digital pharmacy safety gaps, Novo Nordisk’s introductory programs for Wegovy and Ozempic, and Scott Gottlieb’s new role at UnitedHealth are shaping patient access and industry strategy.

Pharma Pulse: Patients Struggle to Identify Safe Online Pharmacies, as Novo Nordisk Launches Access Offers

A review of COVID-19 vaccine access inequities, emerging cardioprotective data for semaglutide, and Experity’s integration with Amazon Pharmacy highlights the shifting dynamics of patient access, clinical innovation, and digital-first care delivery in today’s Pharma Pulse.

Pharma Pulse: Rural Vaccine Gaps, Semaglutide Organ-Protective Benefits, and Amazon Pharmacy’s Urgent Care Expansion Shape Healthcare Outlook

This episode of Pharma Pulse discusses how new analysis shows poor treatment and monitoring rates among young adults with high cholesterol, while national efforts ramp up to identify pharmacy deserts—and one US pharmacy becomes the first to accept cryptocurrency for prescriptions.

Pharma Pulse: Young Adults Skip Cholesterol Care, as Pharmacy Access Gaps Widen and Crypto Enters the Prescription Market

This episode of Pharma Pulse discusses how the FDA’s new plausible mechanism pathway, WeightWatchers’ plans to offer oral Wegovy, and emerging evidence on berberine are shaping the future of obesity and metabolic health care.

Pharma Pulse: FDA Advances New Approval Pathway, as Obesity Care and Metabolic Treatments Gain Momentum

This episode of Pharma Pulse discusses how Dr. Richard Pazdur’s appointment signals a new era for FDA drug evaluation, why hospitals are opposing the government’s 340B pilot program, and how Novartis is expanding its US manufacturing footprint with a new radioligand therapy facility in California.

Pharma Pulse: FDA Appoints Richard Pazdur as CDER Director Amid 340B Tensions and Novartis Expansion

This episode of Pharma Pulse explores how regulators modernize safety information for hormone therapy, new data that reinforces SGLT2 inhibitors’ clinical value, and Arsenal Capital expanding its life sciences logistics portfolio with the ThermoSafe acquisition.

Pharma Pulse: HHS Updates Menopausal Hormone Therapy Labels, as SGLT2 Inhibitors Show Broader Kidney and Heart Benefits

This episode of Pharma Pulse explores a major review finding no link between maternal acetaminophen use and autism or ADHD, CMS launching initiatives to cut Medicaid drug costs, and Eli Lilly expanding its gene therapy collaborations.

Pharma Pulse: New Research and Policy Moves Shape Pharma Landscape

This episode of Pharma Pulse discusses FDA’s growing National Priority Voucher initiative, fresh data on oral semaglutide’s cardiometabolic impact, and Mark Cuban’s latest drug addition that signals key shifts in innovation, access, and affordability across the pharmaceutical landscape.

Editorial Podcasts